Obsessive compulsive disorder in adolescence: an epidemiological study.
Explore the source record for details and available documents.
Adolescent↗
Biomedical subjects
M F Flament
Publications and source records attributed to M F Flament.
Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography.
New brain imaging techniques may provide evidence for a biological basis for severe psychiatric disorders. The authors used quantitative X-ray computed tomography (CT) to analyze the brain volume of 10 male patients with severe primary obsessive-compulsive disorder and 10 healthy male control subjects. Caudate nucleus volume in the patients with obsessive-compulsive disorder was significantly less than that of control subjects, but lenticular nuclei, third ventricle, and lateral ventricle volumes did not differ between these two groups, and no abnormal asymmetry of bilateral structures was detected. These findings support other evidence of involvement of the caudate nucleus in obsessive-compulsive disorder.
Adolescent↗
Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder.
Peripheral measures of serotonergic and noradrenergic function were obtained in 29 obsessive-compulsive adolescents and 31 age- and sex-matched controls, as well as in a subsample of 22 patients after five weeks of treatment with clomipramine hydrochloride (134 +/- 33 mg/d) (mean +/- SD) given in a double-blind placebo-controlled trial. Drug-free obsessive-compulsive subjects did not differ from controls on measures of platelet serotonin and monoamine oxidase (MAO) activity, nor on plasma epinephrine or norepinephrine concentrations at rest and after a standard orthostatic challenge procedure. Compared with placebo, treatment with clomipramine was clinically effective and produced a marked decrease in platelet serotonin concentration, a trend toward a reduction in platelet MAO activity, and a rise in standing plasma norepinephrine. Clinical improvement during drug therapy was closely correlated with pretreatment platelet serotonin concentration and MAO activity, as well as with the decrease in both measures during clomipramine administration. This suggests that the effects of clomipramine on serotonin uptake may be essential to the antiobsessional action observed.
Adolescent↗
Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study.
Nineteen children (mean [+/- SD] age, 14.5 +/- 2.3 years) with severe, primary obsessive-compulsive disorder completed a ten-week, double-blind, controlled trial of clomipramine hydrochloride (mean dosage, 141 mg/day) or placebo, each of which was administered for five weeks. Half of the subjects had not responded to previous treatment with other tricyclic antidepressants. There was a significant improvement in observed and self-reported obsessions and compulsions that was independent of the presence of depressive symptoms at baseline. Improvement in obsessive-compulsive symptoms did not correlate significantly with plasma concentrations of the drug or its metabolites. Clomipramine appears to be effective in the treatment of children with obsessive-compulsive disorder and the treatment seems to be independent of an antidepressant effect.
Adolescent↗
A controlled trial of clomipramine in childhood obsessive compulsive disorder.
Explore the source record for details and available documents.
Adolescent↗
[Comorbidity between eating disorders and anxiety disorders. First part: methodological review].
UNLABELLED: The objective of our work is to conduct a critical literature review on studies assessing the prevalence of anxiety disorders (AD) in subjects with eating disorders (ED) (anorexia nervosa and bulimia nervosa). In the first part (this paper), we will discuss methodological issues relevant to comorbidity studies between ED and AD. METHOD: We performed a manual and computerised search (Medline) for all published studies on comorbidity between ED and AD, limiting our search to the 1985-2002 period, in order to get sufficiently homogeneous diagnostic criteria for both categories of disorders (most often RDC, DSM III, DSM Ill-R, or DSM IV criteria). RESULTS: We review methodological issues regarding population sources, general methodological procedures, diagnostic criteria for ED and AD, diagnostic instruments, age of subjects and course of the eating disorder. DISCUSSION: We give implications for reviewing the results of published studies and planing future research.
Adult↗
[Comorbidity between eating disorders and anxiety disorders: results].
Taking into account the methodological problems underlined in the first part of this paper, the current review aims to answer three questions: 1) Is there convincing evidence that anxiety disorders (AD) are more frequent among women with eating disorders (ED) than among women from the community? 2) Is there convincing evidence that prevalence of AD differs across diagnostic types or subtypes of ED? 3) What is the chronology of appearance of the two disorders? We performed a manual and computerized search (Medline) for all published studies on comorbidity between ED and AD (1985-2002 period), and selected the most relevant studies. An increased risk for AD in subjects with ED has been shown in several community studies, but studies conducted in referred subjects have led to inconstant findings. The answer to the questions remains uncertain, because too few studies included control groups and few studies have compared diagnostic subgroups of ED subjects, with scarce or conflicting results.
Adult↗
[Is depressive disorder linked to anxiety disorder among anorexics and bulimics?].
UNLABELLED: The primaty objective is to determine whether the presence anxiety disorders is related to depressive comorbidity in subjects suffering from ED, while taking into account certain variables which may be related to depression [subjects' age, ED duration, prior incidents of anorexia nervosa in BN subjects, inpatient or outpatient status, nutritional state (as measured by Body Mass Index or BMI)]. Our secondary objective is to evaluate the relative chronology of the onset of anxiety disorders and depressive disorders in anorexic and bulimic subjects. METHOD: We evaluated the frequency of depressive disorders in 271 subjects presenting with a diagnosis of either anorexia nervosa or bulimia, using the Mini International Neuropsychiatric Interview (MINI), DSM IV version. RESULTS: While univariate analyses show that nearly all anxiety disorders are related to major depressive episode (MDE), a separate analysis of each anxiety disorder reveals that they do not all have the same influence in terms of risk of onset of MDE in anorexics and bulimics, when adjusted for univariate variables related to MDE (subjects' age, ED duration, prior incidents of anorexia nervosa in BN subjects, inpatient or outpatient status, nutritional state). Current generalized anxiety is significantly related to lifetime presence of MDE in AN subjects, and to current MDE in AN and BN subjects. Generalized anxiety is the most frequent disorder in AN and BN subjects to according our study; it also appears to be one of the principal predictive factors for MDE, which is 2.4 to 4.2 times more frequent when GAD is present. Diagnosis of OCD has its own particular effect on lifetime risk for MDE in AN subjects, regardless of GAD: it increases the risk of depression by 3.5. It is one of the most frequent anxiety disorders among AN subjects, present in nearly a quarter of them. In bulimics, when GAD is excluded, two factors are related to current diagnosis of MDE: panic disorder and subjects' inpatient or outpatient status. Hospitalized bulimics are diagnosed with current MDE 4.4 times more often than those seen as.
Adult↗
[Comorbidity between eating disorders and mood disorders: review].
OBJECTIVE: Comorbidity between eating disorders (ED) and mood disorders is a major issue when evaluating and treating patients with anorexia nervosa (AN) or bulimia nervosa (BN). In the literature, estimated comorbidity rates of mood disorders in subjects with ED differ widely across studies. Obviously, it is difficult to compare results from various sources because of differences in methods of assessment of depressive symptoms and in diagnostic criteria for both ED and mood disorders. Furthermore, few studies have included control groups, and, since mood disorders are among the most frequent psychiatric disorders in women--with an average estimated lifetime prevalence of 23.9 % (Kessleret al., 1994)--, it is not clear, yet, whether mood disorders are more common among women with an ED (AN or BN) than among women from the community. The only review articles we found on the relationships between ED and mood disorders survey different types of arguments in favour of a link between both categories of disorders, including symptoms, personal and family comorbidity, overlap in biological findings, and treatment results, but do not review in detail available comorbidity data. The aim of this paper is to conduct a critical literature review on studies assessing the prevalence of mood disorders in subjects with an ED (AN or BN). In the first part, we will discuss methodological issues relevant to comorbidity studies between ED and mood disorders, and select the most reliable studies. In the second part, taking into account these methodological considerations raised, we summarize the findings of these studies. METHOD: We performed a manual and computerized search (Medline) for all published studies on comorbidity between ED and AD, limiting our search to the 1985-2002 period, in order to get sufficiently homogeneous diagnostic criteria for both categories of disorders. RESULTS: Too few studies include control groups and few studies have compared diagnostic subgroups of ED subjects, with scarce or conflicting results. DISCUSSION: We reviewed numerous studies here and conclude simply that there are many arguments in favor of elevated rates of MD in ED subjects, but there is no convincing evidence yet. Many questions are left unanswered or have conflicting responses. Our review highlights the need for further studies, which should address several requisites: comorbidity studies should be designed with this as a specific goal, rather than as a secondary aim within other types of studies (such as treatment studies, follow-up studies, etc.). Kendler et al. (1991) state that individuals with two disorders are more likely to present for treatment than individuals with one, therefore, comorbidity rates (which are not in agreement with a special etiologic relationship between BN and depression) may be exaggerated in clinical population results. New studies should include control subjects, matched (at least) for sex and age with ED subjects. Studies should evaluate prevalence of all types of MD in order to yield comparable estimates of MD in general. Comorbidity studies should be conducted on both current and recovered patients, compared to subjects from the community. It is still necessary to demonstrate specificity of findings, i.e. that early onset MD are of specific etiological importance to ED and do not simply increase the risk of later psychopathology in general. Studies should be conducted on larger samples, and all diagnostic subgroups should be considered (restrictive and bulimic anorexics, bulimics with and without history of AN, with or without purging). Multivariate comparisons should be performed, taking into account subject age, sex (if men are included), in- and outpatient status, course of illness, and other possibly relevant variables. Thus, more reliable estimates of the frequency of MD in subjects with ED could provide us with valuable etiologic, therapeutic and prognostic information.
Comorbidity↗
[Predictive factors in social adaptation disorders in anorexic and bulimic patients].
A lifetime diagnosis of at least one anxiety disorder has been found in 13% to 75% of women with BN (Herzog, Keller, Sacks, Yeh, & Lavori, 1992; Schwalberg, Barlow, Alger, & Howard, 1992), and in 20% to 55% of women with AN, (Herzog et al., 1992, Laessle et al., 1989). Wittchen et al., 1998) have observed that the frequency and degree of disabilities and impairments associated with mental disorders in adolescence are strongly related to comorbidity (notably with anxiety disorders). However, as noted by Wonderlich et al., 1997, no study has compared ED individuals with and without comorbid anxiety disorders in terms of clinical or general functioning. The current study was designed to determine whether social avoidance symptoms and/or comorbid lifetime anxiety disorders were predictive factors of social disability in subjects with ED (AN or BN). We focused on two main dimensions of social adaptation, regarding social and professional life. 63 subjects with anorexia nervosa or bulimia nervosa were assessed for lifetime diagnoses of anxiety disorders, childhood history of separation anxiety disorder, social avoidance symptoms, and social disability. Sociodemographic characteristics, lifetime diagnoses of ED and anxiety disorders, and ages at onset of each disorder present, were assessed using the French version of the Composite International Diagnostic Interview (CIDI) (Robins et al., 1988; WHO, 1990). In addition, childhood history of separation anxiety disorder, not included in the CIDI, was assessed using the appropriate section of the Schedule for Schizophrenia and Affective Disorders Lifetime Version--Modified for the study of Anxiety Disorders (SADS-LA-R) (Endicott, Spitzer, 1978; Mannuzza, Fyer, Klein, 1985). Social anxiety symptoms were measured on Liebowitz Social Phobia Scale (Liebowitz, 1987). Social adjustment was assessed using a semi-structured interview, the Groningen Social Disabilities Schedule-Second version (GSDS-II) (Wiersma, De Jong, Ormel, & Kraaij Kamp, 1990). For each of the two outcome variables regarding disability, the Social role and the Occupational role, all subsets logistic regression analysis was performed in accordance to Hosmer and Lemeshow's guidelines (Hosmer and Lemeshow, 1989). Our total sample of 63 subjects included 29 subjects with AN restricting type (27 women, 2 men; 7% with a past history of BN) and 34 subjects with BN purging type (all women; 53% with history of a previous episode of AN). On the Groningen Social Disabilities Schedule, 86% of the anorexics and 65% of the bulimics had disability regarding the "social role", and 86% and 61%, respectively, disability regarding the "occupational role". Using all subsets logistic regression analyses, predictive factors of disability were: 1) for the social role, social avoidance symptom score (p < 0.002) and diagnosis of separation anxiety disorder (p < 0.01); 2) for the occupational role, number of lifetime anxiety disorders (p < 0.01) and diagnosis of separation anxiety disorder (p < 0.06). The present study clearly demonstrates that social avoidance and anxiety disorders are common and important features in the clinical presentation of subjects with AN or BN, and that they can have a negative impact on both their social and their occupational adaptation. Chronicity is a major risk in the ED, in terms of medical and sometimes lethal complications, but also because of the social consequences of these disorders. It is therefore important, in subjects with ED, to identify comorbid conditions linked to social disability, in order to improve global outcome. Recognizing and treating comorbid anxiety disorders in subjects with AN or BN could give better results than treating only the ED, in terms of social as well as global psychopathological outcome.
Adjustment Disorders↗
[Pharmacologic treatment of obsessive compulsive disorder in the child and adolescent].
Although obsessive compulsive disorder (OCD) was considered as a rare and treatment-refractory syndrome, research findings from the past decade have focused new interest on the disorder. Epidemiological studies have shown that prevalence rate of OCD was much higher than previously thought (1% of the general adolescent population), and the discovery of a class of psychiatric drugs specific for OCD has brought new therapeutic options as well as pathophysiological hypotheses for the disorder. Rigorous treatment studies have demonstrated that most OCD patients respond to specific pharmacological therapies. The most studied treatment so far has been clomipramine, which appeared superior to placebo and to other antidepressant drugs (amitriptyline, imipramine, desipramine and clorgyline) in a large number of independent controlled studies. In one placebo-controlled study and one study versus desipramine, clomipramine administered to children and adolescents aged 6 to 18, at mean doses of 141 mg/day and 150 mg/day respectively, was well tolerated and had a significant anti-obsessional effect. The novel antidepressant drugs fluvoxamine and fluoxetine are currently under investigation for the treatment of OCD, especially in children. First results indicate a clinical efficacy similar to that of clomipramine, with lower incidence of side-effects. The few drugs that have been demonstrated to be anti-obsessional share a high potency for the blockade of serotonin reuptake. A serotonergic mechanism has therefore been proposed for anti-obsessional drug action and further strengthened by studies demonstrating correlations between clinical response and changes in several serotonergic markers with clomipramine treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
Adolescent↗